Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Sun Yat-sen University51 enrolled

Overview

The purpose of this single arm, phase Ⅱ clinical trail is to determine the safety and efficacy of paclitaxel (albumin bound),bleomycin and cisplatin or carboplatin in the treatment of recurrent Or metastatic squamous cell carcinoma of the head and neck

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Squamous Cell Carcinoma Of The Head And Neck

Interventions

PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or CarboplatinDRUG

All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * biopsy proved squamous cell carcinoma of the head and neck; * stage IVc according to Union for International Cancer Control (UICC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy; * 18 years or older; without other malignancy; * proper functioning of the major organs. Exclusion Criteria: * allergic to paclitaxel (albumin bound) or bleomycin or cisplatin or carboplatin ; * female within gestation period or lactation; * patients received drug of other clinical trial within 3 months

Locations (1)

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

overall survival

Time frame: 5 years

Central Contacts

Qingqing Cai, PhD

CONTACT

0086-20-87342823 caiqq@sysucc.org.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.